SCHEMBL5339722

SCHEMBL5339722

O=C(NCCc1cccs1)c1cc(Cl)ccc1Cl

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.67
RAB9A P51151 8/20 0.67
TAAR1 Q96RJ0 2/20 0.67
LMNA P02545 4/20 0.67
SMN1; SMN2 Q16637 6/20 0.58
KMT2A Q03164 2/20 0.51
IL1B P01584 1/20 0.51
P2RX7 Q99572 1/20 0.51
MAPT P10636 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HTT P42858 1/20 0.50
BRD4 O60885 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
TP53 P04637 1/20 0.48
MEN1 O00255 1/20 0.47
SNCA P37840 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10441846 0.81 RAB9A (1.00) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL5341390 0.80 NPC1 (0.77) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL1412943 0.77 P2RX7 (0.73) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL2559902 0.77 ALDH1A1 (0.62) NPC1LMNAKMT2AP2RX7ALDH1A1
SCHEMBL30277691 0.77 NPC1 (0.57) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL18360398 0.75 NPC1 (0.52) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL18619479 0.75 NPC1 (0.59) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL4179580 0.74 NPC1 (0.54) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL17807496 0.74 NPC1 (0.58) NPC1RAB9ATAAR1LMNASMN1; SMN2
SCHEMBL13151364 0.73 NPC1 (0.50) NPC1RAB9ATAAR1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
EP-1675844-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE Sterix Limited (GB) 2006-07-05 EP disclosed
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2005-10-13 US disclosed
WO-2005042513-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE STERIX LIMITED (GB) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD17B3 NPC1 1239/4885RAB9A 3856/4885TAAR1 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.